US 12,070,466 B2
D2O stabilized pharmaceutical formulations
Gregory I. Ostrow, San Diego, CA (US); Kenneth J. Widder, Rancho Santa Fe, CA (US); and David S. Baker, Carlsbad, CA (US)
Assigned to SYDNEXIS, INC., Del Mar, CA (US)
Filed by Sydnexis, Inc., Del Mar, CA (US)
Filed on Jun. 1, 2021, as Appl. No. 17/335,496.
Application 17/335,496 is a continuation of application No. 15/578,202, granted, now 11,052,094, previously published as PCT/US2016/034823, filed on May 27, 2016.
Claims priority of provisional application 62/168,538, filed on May 29, 2015.
Prior Publication US 2021/0393649 A1, Dec. 23, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/5575 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 9/08 (2006.01); A61K 31/18 (2006.01); A61K 31/216 (2006.01); A61K 31/565 (2006.01); A61K 31/57 (2006.01); A61K 47/02 (2006.01); A61K 47/34 (2017.01); A61K 47/38 (2006.01); A61P 27/02 (2006.01)
CPC A61K 31/5575 (2013.01) [A61K 9/0048 (2013.01); A61K 9/06 (2013.01); A61K 9/08 (2013.01); A61K 31/18 (2013.01); A61K 31/216 (2013.01); A61K 31/565 (2013.01); A61K 31/57 (2013.01); A61K 47/02 (2013.01); A61K 47/34 (2013.01); A61K 47/38 (2013.01); A61P 27/02 (2018.01)] 18 Claims
 
1. A method of treating an ophthalmic condition or disease comprising administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition comprising about 0.015 wt % to about 1 wt % pilocarpine or a pharmaceutically acceptable salt of pilocarpine, a buffering agent, and deuterated water, at a pD of from about 4 to about 8, wherein the composition comprises less than 10% w/v of a degradant of pilocarpine after at least two weeks under a storage condition.